OC
DNTH icon

Oppenheimer & Co’s Dianthus Therapeutics DNTH Stock Holding History

Oppenheimer & Co’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,250
Closed -$89K – 1498
2021
Q4 		$89K Hold
1,250
– – ﹤0.01% 1451
2021
Q3 		$146K Hold
1,250
– – ﹤0.01% 1426
2021
Q2 		$196K Hold
1,250
– – ﹤0.01% 1422
2021
Q1 		$237K Hold
1,250
– – ﹤0.01% 1271
2020
Q4 		$157K Hold
1,250
– – ﹤0.01% 1275
2020
Q3 		$136K Hold
1,250
– – ﹤0.01% 1208
2020
Q2 		$150K Hold
1,250
– – ﹤0.01% 1159
2020
Q1 		$126K Hold
1,250
– – ﹤0.01% 1094
2019
Q4 		$303K Hold
1,250
– – 0.01% 1017
2019
Q3 		$205K Hold
1,250
– – 0.01% 1128
2019
Q2 		$295K Hold
1,250
– – 0.01% 1015
2019
Q1 		$329K Buy
+1,250
New +$216K 0.01% 999

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Oppenheimer & Co's DNTH Position: Q1 2022 in Review

Oppenheimer & Co sold out of Dianthus Therapeutics (DNTH) in Q1 2022, closing a stake of 1,250 shares — an estimated $89K sold.

Oppenheimer & Co first reported a position in DNTH in Q1 2019 and held it in 12 quarters. The position peaked at $329K in Q1 2019. 93 funds tracked by Wall St. Rank hold DNTH as of Q1 2022.

  • Oppenheimer & Co reported no remaining Dianthus Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Oppenheimer & Co sold 1,250 Dianthus Therapeutics shares in Q1 2022, an estimated $89K.
  • Oppenheimer & Co first reported a position in Dianthus Therapeutics in Q1 2019 and held it in 12 quarters.
  • Oppenheimer & Co's Dianthus Therapeutics position peaked at $329K in Q1 2019.
  • 93 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2022.

Based on Oppenheimer & Co's 13F filing for Q1 2022, filed 12 May 2022.